BCRX

BIOCRYST PHARMACEUTICALS INC

BCRX·09058V103·US·Common Stock·Healthcare - Drug Manufacturers - Specialty & Generic-13D/G

BCRX (BIOCRYST PHARMACEUTICALS INC) is held by 164 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($238.9M), RA CAPITAL MANAGEMENT, L.P. ($158.3M), STATE STREET CORP ($151.9M). Net institutional sentiment: Mixed. In Q2 2026, 1 member of Congress and 103 funds bought BCRX.

164
Holders
(12 Elite)
$1.8B
Total Value
64% (161)
Consensus
103 buying - 58 selling
13F: Insider & Congress: Updated regularly
BCRX

Smart Money Verdict

View all
Loading verdict
Held by 164 funds
12 elite

Who's Trading

Source dates: Price Aug 28, 2026 · Insiders Mar 24, 2026 · Activists Aug 14, 2026 · Congress Dec 15, 2025

ActivistRA Capital Management, L.P.RA Capital Management, L.P.6.2%Aug 14, 2026
ActivistSTATE STREET CORPORATIONSTATE STREET CORPORATION6.0%Aug 7, 2026
ActivistSTATE STREET CORPORATIONSTATE STREET CORPORATION4.9%May 12, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
23.9M(+5.5%)$238.9M0.0%+26.43%
32
Unchanged
15.8M$158.3M1.4%+26.03%
0
Increased
15.2M(+24.4%)$151.9M0.0%+33.29%
37
Increased
11.4M(+2.0%)$113.6M0.0%+3.15%
31
Decreased
11.1M(-0.9%)$111.4M0.0%+3.26%
0
Increased
6.8M(+6.0%)$67.8M0.0%+10.29%
31
Increased
6.2M(+8.1%)$62.5M0.0%+33.36%
32
Increased
5.3M(+5.4%)$53.1M0.1%+6.29%
31
Increased
5.1M(+2.7%)$50.8M0.0%+18.01%
30
Decreased
4.8M(-5.7%)$48M0.0%+7.66%
0
Increased
4.5M(+90.9%)$44.8M0.0%+9.10%
46
Increased
4M(+4.9%)$40.1M0.0%+15.77%
31
Increased
3.4M(+1708.4%)$33.9M0.0%-0.65%
47
Increased
2.8M(+343.7%)$27.6M0.0%+4.05%
46
Increased
2.7M(+1.1%)$27.2M0.0%+12.37%
29
Decreased
2.6M(-4.7%)$26M0.0%-22.13%
0
Increased
2.5M(+225.7%)$25.3M0.0%+3.68%
46
Increased
2.5M(+10.0%)$25.1M0.1%+2.79%
38
Increased
2.4M(+0.1%)$23.5M0.0%+33.17%
28
Increased
2.3M(+7.2%)$22.6M0.0%+15.22%
31

Showing 1-20 of 171

1 / 9
BCRXBCRXBIOCRYST PHARMACEUTICALS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used